PRILOSEC

Compare PRILOSEC  to:
Compare
Compare

Generic Name for PRILOSEC

Omeprazole 10mg, 20mg, 40mg; caps containing e-c delayed release granules.

Legal Classification:

Rx

Pharmacological Class for PRILOSEC

Proton pump inhibitor.

Manufacturer of PRILOSEC

AstraZeneca Pharmaceuticals

Indications for PRILOSEC

Triple therapy (w. amoxicillin + clarithromycin) or dual therapy (w. amoxicillin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of active benign gastric ulcer, active duodenal ulcer, erosive esophagitis (EE), symptomatic GERD. Maintenance of healing of EE. Pathological hypersecretory conditions.

Adult dose for PRILOSEC

Take before eating. Swallow whole, or may mix contents of caps in applesauce and take immediately; do not crush or chew granules; follow with water. Triple therapy: omeprazole 20mg + clarithromycin 500mg + amoxicillin 1g, all every 12 hrs for 10 days; then (if ulcer was present at start): omeprazole 20mg once daily in the AM on days 11–28. Dual therapy (clarithromycin resistance more likely to develop than with triple therapy): omeprazole 40mg once daily in the AM + clarithromycin 500mg three times daily on days 1–14; then (if ulcer was present at start) omeprazole 20mg once daily in the AM on days 15–28. Active duodenal ulcer: 20mg once daily for 4 wks; may continue 4 more wks. Gastric ulcer: 40mg once daily for 4–8 weeks. GERD (no esophageal lesions): 20mg once daily for up to 4 weeks. EE with GERD symptoms: 20mg once daily for 4–8 wks; may give up to 4 more wks (if relapse of erosive esophagitis or GERD symptoms occurs may give additional 4–8 wk course). Maintenance of healing of EE: 20mg once daily. Hypersecretory conditions: initially 60mg once daily, then adjust; doses up to 120mg 3 times daily have been used; give doses >80mg/day in divided doses. Hepatic impairment or Asian: consider reducing dose (esp. for maintenance of healing of EE).

Children's dosing for PRILOSEC

Take before eating. Swallow whole, or may mix contents of caps in applesauce and take immediately; do not crush or chew granules; follow with water. <1yr: not recommended. 1–16yrs: GERD, EE: 5<10kg: 5mg daily. 10<20kg: 10mg daily; ≥20kg: 20mg daily.

Warnings/Precautions for PRILOSEC

Gastric malignancy. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for PRILOSEC

Concomitant atazanavir, nelfinavir: not recommended. Potentiates saquinavir, cilostazol; consider dose reduction of these drugs. May potentiate diazepam, phenytoin, warfarin, tacrolimus. Potentiated by voriconazole; may need to adjust omeprazole dose in Zollinger-Ellison syndrome. May alter absorption of pH-dependent drugs (eg, ketoconazole, digoxin, iron salts, ampicillin). Monitor drugs metabolized by CYP450 (eg, cyclosporine, disulfiram, benzodiazepines). May give antacids concomitantly.

Adverse Reactions for PRILOSEC

Headache, abdominal pain, GI upset, flatulence. Children: also, respiratory system events, fever.

Notes for PRILOSEC

See Amoxil entry for more information on amoxicillin. See Biaxin entry for more information on clarithromycin.

How is PRILOSEC supplied?

Caps 10mg—30
20mg—30, 1000
40mg—30, 100

Related Disease:

Duodenal ulcers {DU}
Erosive esophagitis
GERD {GERD}
Ulcers, duodenal
Ulcers, gastric

Related Resources

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions